Insurance

Mounjaro prior authorization: what insurers require

Mounjaro is a diabetes drug, so its prior authorization is about documenting type 2 diabetes — straightforward if you have it, a dead end if you're seeking it purely for weight loss (that's Zepbound). Below: the criteria, a documentation checklist, the metformin step, the formulary-exception route, and denial fixes.

Written byGLP1Zoom Editorial, Medical content team · Independent editorial

Medically reviewed byGLP1Zoom Editorial Team, Evidence-based editorial review Reviewed Jun 10, 2026

Verified Jul 2026 · re-checked quarterlyBy the GLP1Zoom editorial teamWe compare, we don’t sell

The short answer

Mounjaro PA is about documenting type 2 diabetes— a diagnosis, often A1c, and sometimes a metformin trial. With diabetes it's usually a quick approval. Weight-loss-only use is off-label and typically not covered — for weight loss, the on-label tirzepatide is Zepbound (which also has a sleep-apnea path). If Mounjaro is non-preferred, use a formulary exception.

Key takeaways

Mounjaro PA centers on type 2 diabetes documentation: diagnosis code + often recent A1c, sometimes a prior metformin trial.
Weight-loss-only use of Mounjaro is off-label — insurers typically will NOT approve a PA for it.
For weight loss, the on-label tirzepatide is Zepbound (its own criteria + an often-easier OSA coverage path).
If Mounjaro is non-preferred on your plan, a formulary exception (medical necessity) is the correct route — not a standard PA.
With complete diabetes documentation, decisions typically come within a few business days.

What the PA requires

Requirement	What satisfies it
Type 2 diabetes diagnosis	Documented diagnosis (with code) — the core requirement
A1c values	Recent A1c showing need for treatment or inadequate control
Prior therapy / step	Metformin trial and outcome — or documented intolerance/contraindication
Formulary status	If non-preferred: a medical-necessity rationale for Mounjaro specifically

Why weight-loss requests fail

Mounjaro for weight loss usually isn't covered.It's off-label; the on-label tirzepatide for weight is Zepbound — see Zepbound prior authorization, which also explains the sleep-apnea route that can win coverage even where weight-loss drugs are excluded. Same molecule, different product and label.

If Mounjaro is non-preferred: the exception route

If your plan prefers a different diabetes GLP-1, Mounjaro may sit on a higher tier or behind a step. That's not a criteria problem — it's a formulary problem, and the right tool is a formulary exception: your prescriber argues medical necessity (preferred alternatives failed, caused intolerable side effects, or are contraindicated). See our formulary-exception guide.

Denied? Match the fix

Denial reason	Fix
Missing A1c or diagnosis code	Resubmit with the records
Step therapy (metformin)	Document the metformin trial + outcome, or intolerance
Non-preferred formulary status	Request a formulary exception (medical necessity)
Requested for weight loss	Not an appeal problem — switch to Zepbound (on-label)

Steps: denial appeal · formulary exception · cross-drug PA pillar · Mounjaro insurance coverage.

Typical criteria as of 2026-07; they vary by plan and PBM policies revise quarterly. Confirm your plan's policy. Educational only, not medical or insurance advice.

Providers who prescribe and manage tirzepatide

Common questions about Mounjaro prior authorization

What are the prior authorization criteria for Mounjaro?

Mounjaro is FDA-approved for type 2 diabetes, so its prior authorization is about documenting diabetes — typically a type 2 diabetes diagnosis and often recent A1c values, and sometimes a trial of metformin first. This is usually straightforward when you have diabetes and the chart supports it. Criteria vary by plan, and some plans put diabetes GLP-1s behind step therapy or prefer a different agent, in which case a formulary exception may be needed.

Can I get Mounjaro covered for weight loss?

Generally no. Mounjaro is a diabetes drug; weight-loss-only use is off-label, and insurers typically will not approve a prior authorization for it. The weight-loss version of the same tirzepatide molecule is Zepbound, which has its own weight-loss prior-authorization criteria — and, if you have sleep apnea, an additional and often easier OSA coverage path. If weight loss is your goal, Zepbound is the on-label route.

What documentation do I need for Mounjaro approval?

Your chart should show: a type 2 diabetes diagnosis (with the diagnosis code); recent A1c values demonstrating need or inadequate control; and any prior diabetes medications tried with their outcomes — many plans require a documented metformin trial, or a reason metformin is inappropriate (intolerance or contraindication). If your plan prefers a different GLP-1, you may also need a medical-necessity rationale for Mounjaro specifically.

What if Mounjaro is non-preferred on my plan?

If your plan prefers a different diabetes GLP-1, Mounjaro may be non-preferred — meaning a higher tier or a step requirement. You (or your prescriber) can request a formulary exception, arguing medical necessity: that preferred alternatives failed, caused intolerable side effects, or are contraindicated for you. That is a distinct process from a standard prior authorization. See our formulary-exception guide for the exact steps.

Does Mounjaro require trying metformin first?

On many plans, yes. Metformin is the standard first-line type 2 diabetes medication and is inexpensive, so plans commonly require a documented metformin trial — or a documented reason it is inappropriate — before approving a GLP-1 or dual agonist. If you have taken metformin, ensure the history and outcome (inadequate control, or intolerance) are in your chart before the PA is submitted.

How do I get Mounjaro approved by insurance?

Ensure your chart documents your type 2 diabetes diagnosis and recent A1c, plus any prior diabetes medications tried and their outcomes. Then have your prescriber submit a complete prior authorization. Because this is an on-label diabetes use, approval is usually quick with complete documentation. If denied, check the reason — often a missing A1c, an unmet step-therapy requirement, or non-preferred formulary status — and resubmit, request a formulary exception, or appeal.

What if my Mounjaro PA is denied?

Get the exact reason in writing. Missing A1c or diagnosis documentation is fixed by resubmitting the records; an unmet step is fixed by documenting the metformin trial or intolerance; non-preferred status calls for a formulary exception; and your prescriber can request a peer-to-peer review to resolve clinical questions directly. If you were seeking Mounjaro for weight loss, an appeal generally won't succeed — switch to Zepbound, the on-label weight-loss tirzepatide.

Sources

Mounjaro's FDA indication (type 2 diabetes) is from the label; PA patterns reflect typical PBM diabetes criteria and ADA treatment standards, and vary by plan. Reviewed 2026-07-18. Educational only — confirm your plan's policy.

References(3)

Our sourcing standards →

Mounjaro (tirzepatide) Prescribing Information — type 2 diabetes indicationNIH — US FDA label via DailyMed (2026)
OptumRx — GLP-1 Receptor Agonists Prior Authorization guidelines (diabetes criteria) — OptumRx (PBM medical policy) (2026)
Standards of Care in Diabetes — pharmacologic approaches — American Diabetes Association (2025)

Mounjaro prior authorization: what insurers require

What the PA requires

Requirement	What satisfies it
Type 2 diabetes diagnosis	Documented diagnosis (with code) — the core requirement
A1c values	Recent A1c showing need for treatment or inadequate control
Prior therapy / step	Metformin trial and outcome — or documented intolerance/contraindication
Formulary status	If non-preferred: a medical-necessity rationale for Mounjaro specifically

If Mounjaro is non-preferred: the exception route

Denied? Match the fix

Denial reason	Fix
Missing A1c or diagnosis code	Resubmit with the records
Step therapy (metformin)	Document the metformin trial + outcome, or intolerance
Non-preferred formulary status	Request a formulary exception (medical necessity)
Requested for weight loss	Not an appeal problem — switch to Zepbound (on-label)

Typical criteria as of 2026-07; they vary by plan and PBM policies revise quarterly. Confirm your plan's policy. Educational only, not medical or insurance advice.